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Using a protocol of preoperative autologous blood
donation, Masuda and associates have achieved what is
expected of contemporary pediatric cardiac programs,
namely, the near complete avoidance of homologous
blood transfusion in children weighing more than about
12 kg undergoing operations for simple cardiac defects.
Their method, however, must be time consuming and
anxiety provoking for the child and family, could be an
organizational nightmare for higher volume programs,
and is not without its own inherent risks. These disad-
vantages were not analyzed by the authors nor com-
pared with those of other methods of blood conserva-
tion.
Similar results with transfusion-free cardiac surgery
in this weight range have been achieved in other pro-
grams for years by use of lower pump primes (350 mL
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for infants in our institution), modified ultrafiltration,
and intraoperative autologous donation and by mini-
mizing blood loss while avoiding wastage of shed
blood during the operation. These maneuvers are
straightforward and ought to be achievable at the
authors’ institution. Even for higher risk operations, we
are generally able to avoid additional, expensive agents
such as aprotinin and commercially made fibrin “glue”
while minimizing homologous transfusion. 
Children who are preoperatively anemic may avoid
transfusion by receiving recombinant human erythro-
poietin and iron. Their application to increase red cell
mass before elective operations was approved in the
United States in 1996. The safety and efficacy of this
approach in children undergoing orthopedic surgery, in
children with chronic renal failure, in premature infants
with anemia, and in children with cancer have been
demonstrated. The availability of an oral form of
human erythropoietin strengthens the rationale for
using it in children facing cardiac surgery. A prospec-
tive study to demonstrate the advantage of human ery-
thropoietin in children undergoing cardiac surgery is
sorely needed.
When patients do require a transfusion, a component
that satisfies multiple needs, including repletion of red
cell mass, serum proteins, and functional platelets,
should be used. At our institution, we believe these
needs are met by using “fresh whole blood” (obtained
less than 72 hours before transfusion), especially in
infants. With this strategy, infants undergoing an oper-
ation who do require a transfusion at our institution are
exposed to an average of only 1.7 donors.
All cardiac surgeons have the responsibility of apply-
ing all reasonable strategies to minimize homologous
transfusion. This must be placed in perspective, how-
ever, by knowing the actual risks of transfusion in the
current era. In fact, the Centers for Disease Control and
Prevention have registered only two children in the
United States in whom acquired immunodeficiency
syndrome has developed as a result of transfusion (for
all reasons) in the past 15 years and no cases of trans-
fusion-associated hepatitis C viral infection since 1994.
These results are attributable to a national policy of
viral screening of blood and to the education of donors.
On the other hand, more than two thirds of the world’s
nations do not have policies to ensure a safe blood sup-
ply. Unfortunately, many of these countries have high-
er prevalence rates of transmittable viruses and yet lack
the economic resources to afford expensive pharmaco-
logic means to minimize blood loss during pediatric
cardiac surgery. Cardiac programs in these countries
may stand to benefit from the policy of multiple autol-
ogous donation demonstrated nicely by the authors.
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